Track topics on Twitter Track topics that are important to you
International Therapeutics, Inc. (ITI) is developing a novel anti-viral technology called Nuclear Importation Inhibition (NII) that may be applied against chronic viral disease such as HIV-1, hepatitis B (HBV), and herpes viruses. The technology is the subject of eight issued US patents and a series of foreign filings.
The Company, started in 1999, has set up offices and laboratories in Seattle to test its proprietary compounds using in vitro assays for cellular toxicity and anti-viral activity. ITI is currently in pre-clinical testing of a number of compounds with demonstrated in vitro activities against HIV-1. The lead compound ITI-011 is orally bio-available, with a promising in vitro toxicity profile. Continued development of ITI-011 for animal PK and toxicity is underway. ITI anticipates filing an IND for clinical evaluation of ITI-011 in Phase I human studies, in 2002.
ITI is also pursuing a drug discovery program to identify additional small molecule inhibitors of HIV-1, HBV, and herpes viruses.
600 Broadway Medical
United States of America
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the pricing of its underwritten public offering of 14,285,714 shares of common stock or common stock ...
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of anti...
Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.
(American Association for Cancer Research) The American Association for Cancer Research (AACR), the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (EORTC...
Amicus Therapeutics Inc. (small-molecule therapeutics for rare and orphan diseases) netted $243.2mm in a follow-on public offering of 21.1mm common shares (including the overallotment) at $12.25. The...
Grid Therapeutics LLC (oncology) raised an undisclosed sum in its Series A round, which included investments from lead backer Longview International and Duke University.
Regulatory News: Cerenis Therapeutics (FR0012616852 CEREN PEA PME eligible) (Paris:CEREN) an international biopharmaceutical company dedicated to the discovery and development of innovative therap...
Regulatory News: Cerenis Therapeutics (FR0012616852 CEREN PEA PME eligible) (Paris:CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative thera...
ALDEX GS™ Tablets
ALDEX GS DMTablets
Biologics are the most rapidly growing class of therapeutics, but commonly suffer from low stability. Peroral administration of these therapeutics is an attractive delivery route; however, this route ...
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...
Founded in 2007 by recognized experts in intrathecal drug therapies, CNS Therapeutics is a private company based in St. Paul, Minnesota. CNS Therapeutics develops and markets safe...
Garmin International Inc. is a subsidiary of Garmin Ltd. (Nasdaq: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United State...
Convergent Therapeutics acquires, certifies and distributes specialty pharmaceuticals, prescription drugs and drug/device combinations prescribed or used by specialty physicians in Canada and select i...
LAB International (LAB Pharma and LAB Research) is an integrated drug development company with subsidiaries focused on developing and manufacturing novel therapeutics for the multi-billion dollar inha...
We have published hundreds of International Therapeutics Incorporated news stories on BioPortfolio along with dozens of International Therapeutics Incorporated Clinical Trials and PubMed Articles about International Therapeutics Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of International Therapeutics Incorporated Companies in our database. You can also find out about relevant International Therapeutics Incorporated Drugs and Medications on this site too.
AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...